Molecular MRD is strongly prognostic in patients with <i>NPM1</i>-mutated AML receiving venetoclax-based nonintensive therapyJad Othman, Richard Dillon, Michael J. Austin et al.|Blood|2023Cited by 65
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP deliveryMatthew R. Wilson, Pam McKay, Matthew J. Ahearne et al.|Blood Advances|2020Cited by 54
Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHSJad Othman, Richard Dillon, Michael J. Austin et al.|Blood Neoplasia|2024Cited by 36